Alk-Abello AS (CHIX:ALKBC) YoY EBITDA Growth: 14.47% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ALKBC Alk-Abello AS CHIX:ALKBC
92 GF Score
Price kr221.50
GF Value kr220.99
Valuation Fairly Valued
View Full Analysis

What is Alk-Abello AS YoY EBITDA Growth?

Alk-Abello AS CHIX:ALKBC 92 YoY EBITDA Growth is 14.47% as of Jun. 2026. GuruFocus rates CHIX:ALKBC with a GF Score™ of 92/100 and a GF Value™ of kr220.99 (Fairly Valued).

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Alk-Abello AS's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 14.47%.

Alk-Abello AS's EBITDA per Share for the three months ended in Jun. 2026 was kr2.35.

Alk-Abello AS YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Alk-Abello AS's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS YoY EBITDA Growth Chart

Alk-Abello AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.48 30.10 28.97 52.31 42.88

Alk-Abello AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.53 30.61 56.00 22.61 14.47
CHIX:ALKBC
92GF Score
Alk-Abello AS CHIX:ALKBC
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alk-Abello AS YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Alk-Abello AS's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(8.99-6.292)/ | 6.292 |
=42.88 %

Alk-Abello AS's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(2.35-2.053)/ | 2.053 |
=14.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 14.47% mean?
Alk-Abello AS (CHIX:ALKBC) has a YoY EBITDA Growth of 14.47% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Alk-Abello AS and its competitors.
Is Alk-Abello AS's YoY EBITDA Growth too high?
Alk-Abello AS's current YoY EBITDA Growth is 14.47%. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's YoY EBITDA Growth compare to VRTX and REGN?
Alk-Abello AS's YoY EBITDA Growth of 14.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Alk-Abello AS and its competitors. Alk-Abello AS's current YoY EBITDA Growth is 14.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Fairly Valued. The stock's GF Value™ is kr220.99, compared to a current price of kr221.50 — trading 0.2% above its estimated fair value. The current YoY EBITDA Growth is 14.47%. Alk-Abello AS's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current YoY EBITDA Growth is 14.47% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?

Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued. The current stock price of kr221.50 is trading 0.2% above its estimated GF Value™ of kr220.99. GuruFocus considers Alk-Abello AS to be Fairly Valued.

Key valuation signals for CHIX:ALKBC:

  • YoY EBITDA Growth: 14.47%
  • GF Value™: kr220.99 vs. price of kr221.50 (0.2% above fair value)
  • GF Score™: 92/100

No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alk-Abello AS Business Description

Address Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score

Get the complete analysis for CHIX:ALKBC

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr221.50
Price
kr220.99
GF Value